Skip to main content
Fig. 1 | Orphanet Journal of Rare Diseases

Fig. 1

From: Treatment of relapsing multiple sclerosis in Hungary – consensus recommendation from the Hungarian neuroimmunology society

Fig. 1

The number of medication prescription of pwMS on HET between 2016 and 2021 -based on the data from the National Health Insurance Fund [18]. The DMTs are shown in the order of their approval by the national authorities. Cladribine has been accepted since January 2020 without restriction. The reimbursement of anti-CD20 therapies are available with restriction, the only exception is ocrelizumab for primary progressive MS with unrestricted availability since January 2022. Data on DMTs n < 10, e.g. rituximab are not shown

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172